Stephen Hoge Sells 53,336 Shares of Moderna (NASDAQ:MRNA) Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 53,336 shares of the company’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president directly owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stephen Hoge also recently made the following trade(s):

• On Friday, May 15th, Stephen Hoge sold 53,336 shares of Moderna stock. The stock was sold at an average price of $48.40, for a total transaction of $2,581,462.40.

Moderna Stock Up 11.6%

NASDAQ MRNA traded up $6.40 on Wednesday, reaching $61.80. The company had a trading volume of 12,367,572 shares, compared to its average volume of 9,082,071. The firm has a market capitalization of $24.52 billion, a price-to-earnings ratio of -7.58 and a beta of 1.05. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.35 and a current ratio of 2.41. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $62.30. The company’s fifty day moving average is $49.79 and its 200-day moving average is $44.57.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.02) by ($0.38). The company had revenue of $389.00 million during the quarter, compared to the consensus estimate of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. Moderna’s revenue was up 260.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($2.52) EPS. On average, research analysts forecast that Moderna, Inc. will post -6.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Moderna

Several hedge funds have recently bought and sold shares of MRNA. MUFG Securities EMEA plc acquired a new stake in Moderna in the 2nd quarter valued at about $28,000. Flagship Harbor Advisors LLC acquired a new stake in Moderna in the 4th quarter valued at about $31,000. Canton Hathaway LLC acquired a new stake in Moderna in the 1st quarter valued at about $31,000. Ameriflex Group Inc. lifted its stake in Moderna by 3,775.0% in the 3rd quarter. Ameriflex Group Inc. now owns 1,240 shares of the company’s stock valued at $32,000 after purchasing an additional 1,208 shares during the last quarter. Finally, Cromwell Holdings LLC lifted its stake in Moderna by 39.7% in the 4th quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock valued at $35,000 after purchasing an additional 341 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MRNA has been the subject of several analyst reports. Bank of America raised their price objective on Moderna from $32.00 to $34.00 and gave the company an “underperform” rating in a report on Monday, June 8th. Sanford C. Bernstein restated a “market perform” rating and issued a $45.00 price objective on shares of Moderna in a report on Tuesday, February 17th. Evercore set a $35.00 price objective on Moderna in a report on Tuesday, February 17th. Royal Bank Of Canada raised their price objective on Moderna from $35.00 to $38.00 and gave the company a “sector perform” rating in a report on Monday, May 4th. Finally, Morgan Stanley set a $33.00 price objective on Moderna in a report on Friday, May 1st. Two investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and five have given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and an average target price of $36.60.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA briefing documents for Moderna’s seasonal flu vaccine candidate appear more constructive than investors feared, easing concerns ahead of the June 18 advisory committee meeting and supporting hopes for approval. Article Title
• Positive Sentiment: FDA staff reviewers said Moderna’s flu-shot data may support effectiveness in adults age 65 and older, which could strengthen the case for approval and eventual commercialization. Article Title
• Positive Sentiment: Moderna announced organizational changes, including a new chief commercial officer and expanded responsibilities for President Stephen Hoge, signaling more focus on execution ahead of potential product launches in 2027 and 2028. Article Title
• Neutral Sentiment: Moderna said it will host an Investor Event/Science Day on June 25, which may provide updates on its research pipeline and long-term growth plans. Article Title
• Neutral Sentiment: Reuters reported Moderna is interested in investing in production facilities in Germany, potentially taking advantage of BioNTech plant closures, but this is still an early strategic discussion rather than a confirmed financial catalyst. Article Title
• Negative Sentiment: Some reports noted FDA reviewers also raised questions about the evidence package for Moderna’s flu vaccine, so any approval-related gains could face volatility around the upcoming panel vote. Article Title

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.